Nasal Antisepsis for C. Auris Prevention

Recruiting Phase 4 Interventional Study
Candida Auris Infection Colonization, Asymptomatic
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Prevention
Participants needed
120 (estimated)
Sponsor
Mary K Hayden · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * History of C. auris colonization or infection * Patient in a participating facility Exclusion Criteria: * History of severe allergy to iodine-based products, defined as anaphylaxis or rash * Currently breastfeeding or pregnant * Non-English language speaking
Contacts

Sarah E. Sansom, DO

3125636201

sarah_e_sansom@rush.edu

CONTACT

Mary K. Hayden, MD

3129428727

mhayden@rush.edu

CONTACT